MassMutual Private Wealth & Trust FSB Acquires 18,578 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MassMutual Private Wealth & Trust FSB grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 104.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,326 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,578 shares during the period. MassMutual Private Wealth & Trust FSB owned approximately 0.06% of Jazz Pharmaceuticals worth $4,510,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JAZZ. Bessemer Group Inc. grew its holdings in Jazz Pharmaceuticals by 0.3% during the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after acquiring an additional 92 shares during the period. CIBC Asset Management Inc grew its holdings in Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock worth $243,000 after acquiring an additional 97 shares during the period. Synovus Financial Corp grew its holdings in Jazz Pharmaceuticals by 0.5% during the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock worth $2,365,000 after acquiring an additional 100 shares during the period. Quarry LP grew its holdings in Jazz Pharmaceuticals by 6.3% during the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock worth $209,000 after acquiring an additional 100 shares during the period. Finally, Quadrant Capital Group LLC grew its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. The trade was a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Seamus Mulligan bought 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the purchase, the director now directly owns 100,000 shares in the company, valued at $9,826,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold 19,623 shares of company stock worth $2,710,591 over the last 90 days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $0.02 during midday trading on Friday, hitting $108.28. The company had a trading volume of 977,559 shares, compared to its average volume of 838,951. The business's 50 day simple moving average is $109.72 and its two-hundred day simple moving average is $121.37. The stock has a market cap of $6.67 billion, a PE ratio of 15.25, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the firm earned $2.68 EPS. The firm's quarterly revenue was down .5% on a year-over-year basis. As a group, equities analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on JAZZ shares. Needham & Company LLC reiterated a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.